Selection for TRAIL resistance results in melanoma cells with high proliferative potential
- 25 February 2005
- journal article
- Published by Wiley in FEBS Letters
- Vol. 579 (9), 1940-1944
- https://doi.org/10.1016/j.febslet.2005.02.041
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced ApoptosisOnline Journal of Public Health Informatics, 2004
- Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell LinesOnline Journal of Public Health Informatics, 2004
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003
- Overcoming resistance of cancer cells to apoptosisJournal of Cellular Physiology, 2003
- Apoptosis and melanoma chemoresistanceOncogene, 2003
- Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondriaOncogene, 2003
- TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK PathwaysCirculation, 2003
- Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sitesOncogene, 2000
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999
- Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivoNature Medicine, 1999